2 results
Approved WMORecruiting
Primary(Part I and Part II):- To determine the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) in the QW and/or Q3W regimens of RO7122290 in combination with cibisatamab after pretreatment with obinutuzumab- To characterize the…
Approved WMOCompleted
1. To adapt and optimize the MR protocol to enable multi-parametric dynamic acquisitions during 1 hour of mild-cold exposure.2. To investigate tissue dynamics of metabolic activity of the hypothalamus, BAT, and skeletal muscles, measured by dynamic…